Semax Benefits: Neuroprotective Peptide Research Explained

Semax benefits explained: what this ACTH-derived peptide is, how it may influence BDNF and neuroinflammation, where the human evidence is strongest, and research dosing ranges.

Signal IQ Editorial4 min read · Updated Nov 8, 2026
Semax Benefits: Neuroprotective Peptide Research Explained
In this article
  1. What is Semax?
  2. What the research shows
  3. Limits to keep in mind
  4. Dosing ranges reported in research protocols
  5. Safety
  6. Related compounds
  7. Frequently asked questions
  8. References

Semax is a synthetic peptide derived from a fragment of ACTH, studied for neuroprotection and its influence on brain-derived neurotrophic factor (BDNF). Its human evidence is strongest in acute ischemic stroke, not in healthy cognition, and most trials were run in Russia. It is not FDA-approved in the United States and is treated as a research compound.

Key takeaways
  • Semax is a seven-amino-acid analog of ACTH(4-10), modified so it does not stimulate cortisol release.
  • Preclinical work links it to higher BDNF expression, melanocortin receptor activity and less neuroinflammation.
  • The best clinical data concern recovery after ischemic stroke; benefits for healthy cognition are not directly established.
  • Signal IQ lists research doses of 250 to 500 mcg, one to three times daily, usually intranasal.
  • It is typically studied in the nose, not by injection, and earlier-day timing is preferred.

What is Semax?

Semax was developed in the 1980s at Russia’s Institute of Molecular Genetics, originally to protect the brain from damage after ischemic stroke. It is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, built from a fragment of adrenocorticotropic hormone (ACTH).

The modification removed the part of ACTH that acts on the adrenal glands, so Semax does not stimulate cortisol production. The neurological activity was kept and is the focus of study.

Most research uses an intranasal preparation. The nasal route is thought to give access to the olfactory pathway and avoid some of the blood-brain barrier limits that affect peptides given elsewhere.

What the research shows

BDNF expression

BDNF supports neuron survival, new connections between neurons and long-term potentiation, a synaptic process behind learning and memory. Levels tend to fall with age, stress and poor sleep.

In rats, Semax increased BDNF mRNA in the hippocampus and frontal cortex. One study reported that a single dose produced a sustained rise that outlasted the peptide’s short half-life, which suggests it sets off a gene-expression response instead of acting as BDNF itself.

Ischemic stroke

This is the area with the most human data. A randomized controlled trial of intranasal Semax in the acute phase of ischemic stroke reported lower neurological deficit scores and better functional outcomes than control. Proposed explanations include less glutamate excitotoxicity, quieter inflammatory signaling and higher protective growth factors such as BDNF and NGF.

Neuroinflammation

Semax acts on melanocortin receptors, with MC4R and MC5R as the main targets in the central nervous system. In preclinical models it lowered pro-inflammatory cytokines such as IL-6 and TNF-alpha in brain tissue.

Stress response

Rodent studies under stress conditions reported a blunted cortisol response without sedation, consistent with the role of melanocortin receptors in regulating the HPA axis.

AreaEvidence
BDNF upregulationPreclinical (rodent)
Ischemic stroke recoveryRandomized trial in humans
NeuroinflammationPreclinical
Stress reactivityPreclinical
Focus, memory in healthy peopleAnecdotal; not directly established
Note: Most human trials were conducted in Russia and in people with neurological injury. Applying the findings to healthy cognition is mechanistically reasonable but unproven.

Limits to keep in mind

The clinical base is thin by Western standards. Intranasal delivery is variable, and product quality strongly affects what a person actually receives. Response is also likely to differ with baseline BDNF, melanocortin receptor expression and overall brain health. Learn how to read a peptide COA to understand what testing can and cannot tell you.

Dosing ranges reported in research protocols

The Semax compound page on Signal IQ lists the following. These are descriptions of research use, not personal recommendations.

ItemReported range
Amount per dose250 to 500 mcg
Frequency1 to 3 times daily
RouteMost commonly intranasal
TimingEarlier in the day; late dosing is generally avoided because of possible sleep disruption

Duration is not firmly defined, and most community dosing is not based on large controlled trials. For general math and handling, see how to reconstitute peptides and how to store peptides.

Safety

Reported effects include mild headache, short-lived irritability, increased alertness, sleep disruption and mild nasal irritation with intranasal use. Long-term data are limited. Review peptide side effects and research use vs human use for context.

Note: Semax is a research compound and not approved by the FDA. Discuss any decision with a qualified clinician.

Semax is often discussed with Selank, Pinealon and Thymosin Alpha-1. Compare other options with peptides by goal, read the Semax research profile, or ask Pulse.

Frequently asked questions

Does Semax raise cortisol?

No. The ACTH fragment was modified to remove adrenal-stimulating activity, and some rodent work reports a blunted stress response.

Why is Semax usually intranasal?

The nasal route is thought to reach the brain through the olfactory pathway and sidestep the blood-brain barrier. Injectable use is discussed less and has no established dosing on Signal IQ.

Is Semax proven to improve focus or memory?

Not in healthy people. Reports of better focus and mental stamina are anecdotal, and the strongest human data involve stroke.

When is the best time of day to use it?

Research descriptions favor earlier in the day, since later dosing may disturb sleep in some people.

Is Semax approved by the FDA?

No. It is not approved in the United States and is considered a research compound.

How would someone judge their response?

Researchers emphasize a baseline first, such as sleep, subjective focus and stress markers, so any change can be compared rather than guessed.

References

  1. Gusev EI et al. — Randomized controlled trial of Semax in acute ischemic stroke, Cerebrovascular Diseases, 2005 — pubmed.ncbi.nlm.nih.gov
  2. Dolotov OV et al. — Semax stimulates BDNF expression in rat hippocampus, Neurochemical Research, 2006 — pubmed.ncbi.nlm.nih.gov

Go deeper on Signal IQ

Dosing & protocolSemaxResearch profileSemax

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading